3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2/3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Lymphoma
6
Breast Neoplasms
6
Leukemia
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
4
Sarcoma
3
Osteosarcoma
3
Sarcoma, Synovial
2
Sarcoma, Alveolar Soft Part
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neurofibrosarcoma
2
Liposarcoma
2
Leukemia, T-Cell
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Fallopian Tube Neoplasms
2
Chondrosarcoma, Extraskeletal Myxoid
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
The Neoadjuvant Therapy
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Perivascular Epithelioid Cell Neoplasms
1
Nerve Sheath Neoplasms
1
Neoplasms, Connective and Soft Tissue
1
Interventions
Paclitaxel
2
Letrozole
1
Lapatinib
1
Gonadotropin-Releasing Hormone
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Ductal, Breast
×
Doxorubicin
×
Clear all
NCT01426880
2016-02-15
GeparSixto
GBG Forschungs GmbH
Phase 2/3
Completed
595 enrolled